Loading...
NASDAQ: ABCM
Abcam plc
Healthcare · Biotechnology
Market Cap
$5.52B
52w High
$25.32
52w Low
$12.48
P/E
578.45
Volume
7.43M
Outstanding Shares
230.15M
Company profile
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery.
CEOAlan Thomas Hirzel BS,
SectorHealthcare
IndustryBiotechnology
Employees1,760
IPO dateOct 22, 2020
Valuation
Forward P/E—
EV/EBITDA72.05
Enterprise value$3.08B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth21.17%
Gross margin71.21%▲15.24%vs FY2021
Operating margin2.03%▼128.44%vs FY2021
ROE-1.17%▼132.43%vs FY2021
Analyst consensus
RatingHold
Target price—
1
Buy
4
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 31, 2023
View
EPS
Actual vs estimate by quarter
Q4FY22
ActualEst.
-$0.04
$0.19
Q1'23
ActualEst.
$0.04
—
Q3'23
ActualEst.
$0.04
—
Q1FY23
Next Est.
—
Revenue
Actual vs estimate by quarter
Q4FY22
ActualEst.
$166.7M
—
Q1'23
ActualEst.
$101.6M
—
Q3'23
ActualEst.
$101.6M
—
Q1FY23
Next Est.
—